Blood cancer drugs market to reach $111.86 billion by 2030
The global blood cancer drugs market is projected to grow from $84.59 billion in 2026 to $111.86 billion by 2030, according to The Business Research Company. Growth is being driven by rising leukemia, lymphoma and myeloma cases, along with wider use of targeted therapies, immunotherapy and stem cell treatments.
Why it matters: - Blood cancer drugs are becoming more important as global diagnoses rise and treatment options expand. - The market outlook points to sustained demand for therapies that can improve survival, reduce side effects and support long-term care. - The growth signal matters for drug makers, hospitals and cancer care systems investing in hematologic oncology.
What happened: - The Business Research Company published its Blood Cancer Drugs Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report estimates the market will grow from $79.6 billion in 2025 to $84.59 billion in 2026. - The report projects the market will reach $111.86 billion by 2030. - The report says the market is set to expand at a 6.3% CAGR in the historical period and a faster 7.2% CAGR through 2030.
The details: - The report links near-term growth to higher leukemia and lymphoma prevalence, broader chemotherapy use, more oncology hospitals, wider availability of monoclonal antibodies and better diagnostics. - Future growth is tied to precision oncology, stem cell therapy adoption, biologic drug innovation, higher healthcare spending and more cancer screening. - The market includes chemotherapy, biological therapies, targeted therapies, radiation and stem cell transplantation. - These therapies are used to slow disease progression and improve patient outcomes by tailoring treatment to individual needs. - The report identifies targeted therapies, immunotherapy for hematologic cancers, combination regimens and personalized medicine as key trends. - North America held the largest share of the market in 2025. - The Middle East is forecast to be the fastest-growing region in the coming years. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America and Africa. - The report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.
Between the lines: - The forecast suggests blood cancer treatment is shifting toward more specialized and higher-value therapies. - Stronger growth in targeted and personalized treatments often signals a market moving away from one-size-fits-all chemotherapy. - The regional split suggests mature markets still dominate revenue, while faster adoption in newer markets could widen access and competition.
What's next: - Drug developers and oncology providers are likely to focus more on precision medicines, immunotherapy combinations and stem cell-based approaches. - Rising diagnosis rates and screening programs should keep pressure on health systems to expand treatment capacity. - Regional growth outside North America may create new commercial opportunities for manufacturers and distributors. - More information is available in the full report and the free sample.
The bottom line: - Blood cancer drugs are moving into a faster-growth phase, driven by rising cases and a shift toward more precise, combination-based treatments.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
STEM News Today
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.